CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| ADVL1614 | COG | A Phase 1/2 Study of VX15/2503 (IND #136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors | Pediatric CIRB | Available to Open |
| AOST1322 | COG | A Phase II Study of Eribulin (IND# 122686; NSC# 707389) in Recurrent or Refractory Osteosarcoma: An Intergroup NCTN Phase II Study | Pediatric CIRB | Completed |
| ACCL0431 | COG | A Randomized Phase III Study of Sodium Thiosulfate (IND#72877; NSC#45624) for the Prevention of Cisplatin-Induced Ototoxicity in Children: A Groupwide Phase III Study | Pediatric CIRB | Completed |
| ALTE22C1 | COG | Chronic Health Conditions in Down Syndrome-Associated Acute Leukemia: The Down Syndrome Phenotyping Acute Leukemia Study in Survivors (DS-PALS Survivors) | Pediatric CIRB | Available to Open |
| PEPN1812 | PEP-CTN | A Phase 1 Trial of the CD123 X CD3 DART® Molecule Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia | Pediatric CIRB | Available to Open |
| AGCT0521 | COG | Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors with Paclitaxel; Ifosfamide and Carboplatin: A Groupwide Phase II Study | Pediatric CIRB | Completed |
| ADVL1521 | COG | A Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia | Pediatric CIRB | Available to Open |
| ACNS1123 | COG | Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT): A Groupwide Phase II Study | Pediatric CIRB | Available to Open |
| ARST03P1 | COG | A Pilot Phase II Study for Children with Infantile Fibrosarcoma | Pediatric CIRB | Completed |
| ADVL1823 | COG | Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias | Pediatric CIRB | Available to Open |